Prevalence of Y-Chromosome Sequences and Gonadoblastoma In
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Pure Choriocarcinoma of the Ovary: a Case Report
Case Report J Gynecol Oncol Vol. 22, No. 2:135-139 pISSN 2005-0380 DOI:10.3802/jgo.2011.22.2.135 eISSN 2005-0399 Pure choriocarcinoma of the ovary: a case report Lin Lv1, Kaixuan Yang2, Hai Wu1, Jiangyan Lou1, Zhilan Peng1 Departments of 1Obstetrics and Gynecology and 2Pathology, West China Second University Hospital, Sichuan University, Chengdu, Sichuan, China Pure ovarian choriocarcinomas are extremely rare and aggressive tumors which are gestational or nongestational in origin. Due to the rarity of the tumor, there is a lack of information on the clinicopathologic features, diagnosis, and treatment. We report a case of a pure ovarian choriocarcinoma, likely of nongestational origin, treated by cytoreductive surgery in combination with postoperative chemotherapy. The patient was free of disease after a 12month followup. Keywords: Choriocarcinoma, Nongestational, Ovary INTRODUCTION CASE REPORT Pure ovarian choriocarcinomas are extremely rare malignan A 48yearold woman was admitted to our department cies which are of gestational or nongestational in origin. with a 6month history of irregular vaginal bleeding and a The gestational type may arise from an ectopic ovarian pre 1month history of a palpable abdominal mass. She had a gnancy or present as a metastasis from a uterine or tubal nor mal vaginal delivery at 26 years of age and had no recent choriocarcinoma, while the nongestational type is a rare history of normal pregnancies, molar gestations, or abortions. germ cell tumor with trophoblastic differentiation. The esti The physical examination revealed abdominal tenderness and mated incidence of gestational ovarian choriocarcinomas a fixed mass arising from the pelvis to 3 cm below the um is 1 in 369 million pregnancies [1]. -
Discovery of Candidate Genes for Stallion Fertility from the Horse Y Chromosome
DISCOVERY OF CANDIDATE GENES FOR STALLION FERTILITY FROM THE HORSE Y CHROMOSOME A Dissertation by NANDINA PARIA Submitted to the Office of Graduate Studies of Texas A&M University in partial fulfillment of the requirements for the degree of DOCTOR OF PHILOSOPHY August 2009 Major Subject: Biomedical Sciences DISCOVERY OF CANDIDATE GENES FOR STALLION FERTILITY FROM THE HORSE Y CHROMOSOME A Dissertation by NANDINA PARIA Submitted to the Office of Graduate Studies of Texas A&M University in partial fulfillment of the requirements for the degree of DOCTOR OF PHILOSOPHY Approved by: Chair of Committee, Terje Raudsepp Committee Members, Bhanu P. Chowdhary William J. Murphy Paul B. Samollow Dickson D. Varner Head of Department, Evelyn Tiffany-Castiglioni August 2009 Major Subject: Biomedical Sciences iii ABSTRACT Discovery of Candidate Genes for Stallion Fertility from the Horse Y Chromosome. (August 2009) Nandina Paria, B.S., University of Calcutta; M.S., University of Calcutta Chair of Advisory Committee: Dr. Terje Raudsepp The genetic component of mammalian male fertility is complex and involves thousands of genes. The majority of these genes are distributed on autosomes and the X chromosome, while a small number are located on the Y chromosome. Human and mouse studies demonstrate that the most critical Y-linked male fertility genes are present in multiple copies, show testis-specific expression and are different between species. In the equine industry, where stallions are selected according to pedigrees and athletic abilities but not for reproductive performance, reduced fertility of many breeding stallions is a recognized problem. Therefore, the aim of the present research was to acquire comprehensive information about the organization of the horse Y chromosome (ECAY), identify Y-linked genes and investigate potential candidate genes regulating stallion fertility. -
Male Genital Cancers in the US in 2015 Frequency of Types
5/22/2015 Male Genital Cancers in Germ Cell Tumors of the Testis the US in 2015 Pathology, Immunohistochemistry, and the Often Confusing Estimated Number Site Appearance of Their Metastases of Cases Prostate 220,800 Charles Zaloudek, MD Bladder 56,320 Department of Pathology Kidney 38,270 UCSF Testis 8430 Germ Cell Tumors of the Testis Frequency of Types Intratubular Germ Cell Neoplasia, Unclassified (IGCNU) Intratubular Germ Cell Neoplasia, Specific Types • Seminoma is the Tumor Type % Seminoma most common pure type Spermatocytic Seminoma Mixed GCT 78 Embryonal Carcinoma • Mixed germ cell Embryonal Yolk Sac Tumor tumor is the most 16 Choriocarcinoma common CA Other Trophoblastic Tumors nonseminomatous Teratoma 5 Teratoma germ cell tumor Yolk Sac 2 Mixed Germ Cell Tumor Tumor Calgary, Canada Mod Pathol 2013; 26: 579-586 1 5/22/2015 Intratubular Germ Cell Neoplasia (Carcinoma in Situ) • Precursor of most invasive germ cell tumors • Most likely in high risk patients; found in <1% of the normal population • Thought to be established in the fetus at the time the gonads develop • Switched on at puberty • Lacks 12p abnormalities found in invasive tumors • 50% develop invasive germ cell tumor by 5 years, 70% by 7 years Advances in Anatomic Pathology 2015; 22 (3): 202-212 I had a couple of previous papers returned from American journals, which for a long time did not appreciate the existence of a CIS pattern. However, even there, CIS is now officially recognized…. 2002 2 5/22/2015 The Background IGCNU IGCNU – OCT4 3 5/22/2015 IGCNU – SALL4 IGCNU – CD117 IGCNU – Pagetoid Spread to the Rete Testis Treatment of IGCNU • Unilateral: Orchiectomy • Bilateral: Low dose radiation – Prevents development of invasive germ cell tumor – Causes sterility 4 5/22/2015 Staging Testicular Tumors Clinical Stage I • Limited to testis and epididymis. -
Non-Gestational Choriocarcinoma of the Ovary Complicated by Dysgerminoma: a Case Report
6 Case Report Page 1 of 6 Non-gestational choriocarcinoma of the ovary complicated by dysgerminoma: a case report Chi Zhang1,2,3, Yangmei Shen1,2 1Department of Pathology, West China Second University Hospital of Sichuan University, Chengdu, China; 2Key Laboratory of Birth Defects and Related Diseases of Women and Children (Sichuan University), Ministry of Education, West China Second Hospital, Sichuan University, Chengdu, China; 3The Third Affiliated Hospital of Xinxiang Medical University, Xinxiang, China Correspondence to: Yangmei Shen. Department of Pathology, West China Second University Hospital of Sichuan University, Chengdu 610041, China; Key Laboratory of Birth Defects and Related Diseases of Women and Children (Sichuan University), Ministry of Education, West China Second Hospital, Sichuan University, Chengdu, China. Email: [email protected]. Abstract: To report a case of non-gestational ovarian choriocarcinoma complicated by dysgerminoma and summarize its clinical manifestations, pathological features, treatment, and prognosis. The clinical manifestations, histomorphological features, and immunohistochemical staining findings of a patient with choriocarcinoma complicated by dysgerminoma were recorded. Computed tomography and vaginal color Doppler ultrasound in the outpatient department of our hospital showed that there were large, cystic or solid masses in the pelvic and abdominal cavities, which were considered to be malignant tumors originating from adnexa. Extensive hemorrhage and necrosis were seen in tumor tissues, which were composed of two tumor components: one tumor component contained cytotrophoblasts and syncytiotrophoblasts, and had no placental villous tissue; the other tumor component consisted of medium-sized, round or polygonal cells. Germ cell tumors were considered based on the histological morphological features of the HE-stained slices. -
Gestational Trophoblastic Disease Causes, Risk Factors, and Prevention Risk Factors
cancer.org | 1.800.227.2345 Gestational Trophoblastic Disease Causes, Risk Factors, and Prevention Risk Factors A risk factor is anything that affects your chance of getting a disease such as cancer. Learn more about the risk factors for gestational trophoblastic disease. ● What Are the Risk Factors for Gestational Trophoblastic Disease? ● Do We Know What Causes Gestational Trophoblastic Disease? Prevention At this time not much can be done to prevent gestational trophoblastic disease. ● Can Gestational Trophoblastic Disease Be Prevented? What Are the Risk Factors for Gestational Trophoblastic Disease? A risk factor is anything that affects your chance of getting a disease such as cancer. Different cancers have different risk factors. For example, exposing skin to strong sunlight is a risk factor for skin cancer. Smoking is a risk factor for cancers of the lung, mouth, larynx (voice box), bladder, kidney, and several other organs. 1 ____________________________________________________________________________________American Cancer Society cancer.org | 1.800.227.2345 But risk factors don't tell us everything. Having a risk factor, or even several risk factors, does not mean that you will get the disease. And some people who get the disease might not have any known risk factors. Even if a person has a risk factor, it is often very hard to know how much that risk factor may have contributed to the cancer. Researchers have found several risk factors that might increase a woman's chance of developing gestational trophoblastic disease (GTD). Age GTD occurs in women of childbearing age. The risk of complete molar pregnancy is highest in women over age 35 and younger than 20. -
Soft Computing in Bioinformatics Outline
Soft Computing in Bioinformatics James M. Keller and Mihail Popescu Electrical and Computer Engineering Department Health Management and Informatics Department University of Missouri-Columbia With a lot of help from our friends at MU, Univ of Utah, Univ. West FL and Indian Statistical Institute Outline I. Background 1. Genes and Gene Products i. Sequences ii. Structure 2. Microarrays (expression, hypermethylation) 3. Taxonomies: Gene Ontology and MeSH. II. Gene Product Similarity Measures 1. Introduction 2. Dot-Plot 3. Smith-Waterman 4. BLAST 5. GO-based measures i. Jaccard, Cosine, Dice ii. Fuzzy measures iii. Choquet Integrals 6. Domain and Motif measures 05/22/2005 2 1 Outline (Continued) III. Visualization and Clustering 1. Hierarchical clustering 2. Visual Assessment of cluster Tendency 3. FCM and NERFCM 4. Bi-clustering (AKA co-clustering, two-way clustering) IV. Knowledge Discovery 1. Functional annotation of gene products 2. Functional Clustering of proteins in families 3. Summarization of a set of gene products 4. Hot applications: i. Methylation microarrays ii. Learning biochemical networks from microarray data 05/22/2005 3 I. Background 2 Introduction • Principal features of gene products are – the sequence and expression values following a microarray experiment • Sequence comparisons – DNA, Amino Acids, Motifs, Secondary Structure • For many gene products, additional functional information comes from – the set of Gene Ontology (GO) annotations and – the set of journal abstracts related to the gene (MeSH annotations) • For -
Testicular Mixed Germ Cell Tumors
Modern Pathology (2009) 22, 1066–1074 & 2009 USCAP, Inc All rights reserved 0893-3952/09 $32.00 www.modernpathology.org Testicular mixed germ cell tumors: a morphological and immunohistochemical study using stem cell markers, OCT3/4, SOX2 and GDF3, with emphasis on morphologically difficult-to-classify areas Anuradha Gopalan1, Deepti Dhall1, Semra Olgac1, Samson W Fine1, James E Korkola2, Jane Houldsworth2, Raju S Chaganti2, George J Bosl3, Victor E Reuter1 and Satish K Tickoo1 1Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA; 2Cell Biology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA and 3Department of Internal Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA Stem cell markers, OCT3/4, and more recently SOX2 and growth differentiation factor 3 (GDF3), have been reported to be expressed variably in germ cell tumors. We investigated the immunohistochemical expression of these markers in different testicular germ cell tumors, and their utility in the differential diagnosis of morphologically difficult-to-classify components of these tumors. A total of 50 mixed testicular germ cell tumors, 43 also containing difficult-to-classify areas, were studied. In these areas, multiple morphological parameters were noted, and high-grade nuclear details similar to typical embryonal carcinoma were considered ‘embryonal carcinoma-like high-grade’. Immunohistochemical staining for OCT3/4, c-kit, CD30, SOX2, and GDF3 was performed and graded in each component as 0, negative; 1 þ , 1–25%; 2 þ , 26–50%; and 3 þ , 450% positive staining cells. The different components identified in these tumors were seminoma (8), embryonal carcinoma (50), yolk sac tumor (40), teratoma (40), choriocarcinoma (3) and intra-tubular germ cell neoplasia, unclassified (35). -
Case Report Non-Gestational Choriocarcinoma As a Cause Of
Bangladesh Journal of Medical Science Vol. 19 No. 04 October’20 Case report Non-gestational choriocarcinoma as a cause of heavy menstrual bleeding-potential: Primary care detection Allen Chai Shiun Chat1, Nani Draman2*, Siti Suhaila Mohd Yusoff3, Rosediani Muhamad4 Abstract: Choriocarcinoma is a malignant trophoblastic disease. It can be divided into gestational and non-gestational type. Gestational choriocarcinoma consists of less than 1% of total endometrial malignancy, and usually is diagnosed via histopathological examination preceding a suspected molar pregnancy. In contrast to gestational choriocarcinoma, only a few cases of primary non-gestational choriocarcinoma were reported in literature reviews. The reported locations for primary non-gestational choriocarcinoma were ovarian and uterine cervix. Due to its low incidence, this disease is often overlooked leading, to delayed diagnosis. In primary care practice, heavy menstrual bleeding is a common presentation. Further evaluations, such as full blood count, ultrasound pelvis or hysteroscopy are usually required. We would like to report a case of potentially earlier detection of non-gestational choriocarcinoma in a 52 years old lady who was presented with heavy menstrual bleeding for a duration of one year. Her symptom persisted despite receiving medical treatment in a few local primary care clinics. She was admitted to a tertiary hospital for symptomatic anaemia which required blood transfusion. Further evaluations, (i.e., laboratory tests, ultrasound, Computed Topography (CT) scan, bone scan, hysteroscopy and laparotomy total abdominal hysterectomy and bilateral salphingo-oophorectomy (TAHBSO) and histological examination) concluded a diagnosis of primary non-gestational choriocarcinoma of fundal uterus with lung metastasis. Keywords: Abnormal uterine bleeding; Heavy menstrual; Primary non-gestational choriocarcinoma of uterus; Pervaginal bleeding Bangladesh Journal of Medical Science Vol. -
Laparoscopically Removed Streak Gonad Revealed Gonadoblastoma
ANTICANCER RESEARCH 37 : 3975-3979 (2017) doi:10.21873/anticanres.11782 Laparoscopically Removed Streak Gonad Revealed Gonadoblastoma in Frasier Syndrome KAZUNORI HASHIMOTO 1, YU HORIBE 1, JIRO EZAKI 2, TOSHIYUKI KANNO 1, NOBUKO TAKAHASHI 1, YOSHIKA AKIZAWA 1, HIDEO MATSUI 1, TOMOKO YAMAMOTO 2 and NORIYUKI SHIBATA 2 Departments of 1Obstetrics and Gynecology, and 2Pathology, Faculty of Medicine, Tokyo Women’s Medical University, Tokyo, Japan Abstract. Background: Frasier syndrome (FS) is case of primary amenorrhea with nephropathy. Prophylatic characterized by gonadal dysgenesis and progressive gonadectomy is recommended due to the high risk of nephropathy caused by mutation in the Wilm’s tumor gene gonadoblastoma in the dysgenetic gonad. (WT1). We report a case of FS in which diagnosis was based on amenorrhea with nephropathy, and laparoscopically- Frasier syndrome (FS) is characterized by male removed streak gonad which revealed gonadoblastoma. Case pseudohermaphroditism and nephropathy, and was first Report: At the age of 3 years, the patient developed described in 46, XY monozygotic twins in 1964 (1). FS is nephrotic syndrome. This later became steroid-resistant and, caused by heterozygous de novo intronic splice site mutations by the age of 16 years, had progressed to end-stage renal in the Wilms’ tumor suppressor gene ( WT1 ), which is a failure with peritoneal dialysis. At the age of 17 years, the regulator of early gonadal and renal development (2). patient presented primary amenorrhea and was referred to We report here a case of FS diagnosed based on our department. Physical examination was consistent with amenorrhea with nephropathy, and laparoscopically removed Tanner 1 development and external genitalia were female streak gonad which revealed gonadoblastoma. -
Pathogenesis of Intracranial Germ Cell Tumors Reconsidered
Neurosurg Focus 5 (1):Article 1, 1998 Pathogenesis of intracranial germ cell tumors reconsidered Keiji Sano, M.D., D.M.Sc. Department of Neurosurgery, Fuji Brain Institute, University of Tokyo, and Department of Neurosurgery, Teikyo University, Tokyo, Japan The author studied 153 cases of intracranial germ cell tumors (GCTs) through 1994, 62.7% of which showed monotypic histological patterns and 37.3% of which were shown to be mixed tumors. All of these cases, except for six patients who died soon after admission and underwent autopsy, underwent surgery followed by radio- and/or chemotherapy. All patients with choriocarcinoma died within 2 years. Patients with yolk sac tumor (endodermal sinus tumor) and embryonal carcinoma also had poor outcomes. Patients with mature teratoma had 5- and 10-year survival rates of 92.9% each. Patients with immature teratoma and malignant teratoma had a 5- and 10-year survival rate of 70.7% each. Patients with germinoma had a 5-year survival rate of 95.4% and a 10-year survival rate of 92.7%. These results may bring into question the validity of the germ cell theory, because germinoma, which should be the most undifferentiated according to the theory, was the most benign and choriocarcinoma and yolk sac tumor (endodermal sinus tumor), which should be the most differentiated, were the most malignant according to results obtained during follow-up study. Therefore, GCTs other than germinoma may not originate from one single type of cell (primordial germ cells). The embryonic cells of various stages of embryogenesis may perhaps be misplaced in the bilaminar embryonic disc at the time of the primitive streak formation, becoming involved in the stream of lateral mesoderm and carried to the future cranial area to become incorrectly enfolded into the brain at the time of the neural tube formation. -
TSPY1L Antibody (Pab)
21.10.2014TSPY1L antibody (pAb) Rabbit Anti-Human/Mouse Testis specific protein Y-linked 1 large isoform ( TSPY, CT78, DYS14, pJA923) Instruction Manual Catalog Number PK-AB718-7121 Synonyms TSPY1L Antibody: Testis specific protein Y-linked 1 large isoform, TSPY, CT78, DYS14, pJA923 Description Testis-specific protein on Y chromosome (TSPY1) is an ampliconic gene on the Y chromosome that has been associated with gonadoblastoma. Recent experiments have shown that in androgen- dependent testicular germ-cell tumors, TSPY1 can repress the androgen-bound androgen receptor (AR), a member of the nuclear steroid hormone receptor family that acts as a ligand-inducible transcription factor, suggesting that TSPY1 is a repressor of cell proliferation in germ-cell tumors and potentially in normal gonadal cells during early development. Two distinct isoforms of TSPY1, TSPY1L and TSPY1S, are known to exist. Quantity 100 µg Source / Host Rabbit Immunogen Rabbit polyclonal TSPY1L antibody was raised against a 20 amino acid peptide near the carboxy terminus of human TSPY1L. Purification Method Affinity chromatography purified via peptide column. Clone / IgG Subtype Polyclonal antibody Species Reactivity Human, Mouse Specificity TSPY1L antibody is human and mouse reactive. At least three isoforms of TSPY1 are known to exist; this antibody will detect only TSPY1L. Formulation Antibody is supplied in PBS containing 0.02% sodium azide. Reconstitution During shipment, small volumes of antibody will occasionally become entrapped in the seal of the product vial. For products with volumes of 200 μl or less, we recommend gently tapping the vial on a hard surface or briefly centrifuging the vial in a tabletop centrifuge to dislodge any liquid in the container’s cap. -
Characterizing Genomic Duplication in Autism Spectrum Disorder by Edward James Higginbotham a Thesis Submitted in Conformity
Characterizing Genomic Duplication in Autism Spectrum Disorder by Edward James Higginbotham A thesis submitted in conformity with the requirements for the degree of Master of Science Graduate Department of Molecular Genetics University of Toronto © Copyright by Edward James Higginbotham 2020 i Abstract Characterizing Genomic Duplication in Autism Spectrum Disorder Edward James Higginbotham Master of Science Graduate Department of Molecular Genetics University of Toronto 2020 Duplication, the gain of additional copies of genomic material relative to its ancestral diploid state is yet to achieve full appreciation for its role in human traits and disease. Challenges include accurately genotyping, annotating, and characterizing the properties of duplications, and resolving duplication mechanisms. Whole genome sequencing, in principle, should enable accurate detection of duplications in a single experiment. This thesis makes use of the technology to catalogue disease relevant duplications in the genomes of 2,739 individuals with Autism Spectrum Disorder (ASD) who enrolled in the Autism Speaks MSSNG Project. Fine-mapping the breakpoint junctions of 259 ASD-relevant duplications identified 34 (13.1%) variants with complex genomic structures as well as tandem (193/259, 74.5%) and NAHR- mediated (6/259, 2.3%) duplications. As whole genome sequencing-based studies expand in scale and reach, a continued focus on generating high-quality, standardized duplication data will be prerequisite to addressing their associated biological mechanisms. ii Acknowledgements I thank Dr. Stephen Scherer for his leadership par excellence, his generosity, and for giving me a chance. I am grateful for his investment and the opportunities afforded me, from which I have learned and benefited. I would next thank Drs.